Stelara: first interleukin inhibitor approved for use in Crohn’s diseaseNew intravenous solution for single-dose induction, followed by subcutaneous maintenance therapy. Clinical Feature: Loperamide misuseTake steps to identify patients at risk, minimize harm and prevent misuse. Health Canada examines safety of ondansetron used off-label for nausea and vomiting of pregnancy A link with birth defects could not be confirmed or ruled out. Two new products now available without a prescription in most Canadian provinces Esomeprazole 20 mg and ibuprofen extended-release 600 mg move to nonprescription status. A mysterious abdominal pain declares itself with time PPIs linked to increased risk of chronic kidney disease and progression to end-stage renal disease Risk of adverse renal outcomes increases with duration of PPI use beyond 30 days. ASA use for the primary prevention of cardiovascular disease and colorectal cancer US task force issues updated recommendations that balance benefits and harms. Proton pump inhibitor use may be associated with increased dementia risk A 1.4-fold increased risk of dementia seen in elderly patients using PPIs regularly. Task force recommends against colonoscopy for routine colorectal cancer screening PPIs linked with kidney disease First Previous 12 13 14 15 16 Next Last
